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Introduction: In France, pre-employment screening for tuberculosis (TB) is performed for healthcare workers (HCW).
Screening is repeated when exposure to TB patients or infectious material occurs. The results of these TB screenings
were analysed in a retrospective analysis.
Method: Tuberculin skin tests (TST) and interferon-gamma release assays (QuantiFERON® Gold In-Tube – QFT) were
used to perform the TB screenings. The screening results of 637 HCWs on whom QFT was performed were taken
from the records of the University Hospital of Nantes.
Results: In three (0.5%) HCW, the QFT was indeterminate. In 22.2%, the QFT was positive. A second QFT was
performed in 118 HCWs. The reversion rate was 42% (5 out of 17). The conversion rate was 6% (6 out of 98). A TST
was performed on 466 (73.5%) of the HCWs. Results for TST > 10 mm were 77.4%. In those with a TST < 10 mm, QFT
was positive in 14% and in those with a TST ≥ 10 mm, QFT was positive in 26.7%. Depending on the definition for
conversion in the QFT, the annual attack rate was 4.1% or 7.3%. X-ray and pneumology consultation was based on
positive QFT rather than TST alone (52 out of 56). No active TB was detected.
Conclusion: The TST overestimated the prevalence of LTBI in this cohort. The decision about X-ray and
consultation regarding preventive treatment should be based on the QFT rather than the TST results. The high
reversion rate should be taken into consideration when consulting with HCWs regarding preventive treatment. The
high conversion rate seems to indicate that preventive measures such as wearing masks should be improved.
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Healthcare workers’ (HCW) increased risk of contracting
tuberculosis (TB) is well documented [1-3]. TB screen-
ing for HCWs is therefore considered a cornerstone for
preventing TB in hospitals [4]. Until now, TB screening
was performed using a tuberculin skin test (TST), which
has several weaknesses, the most important being cross-
reactivity with BCG vaccination, booster phenomena
due to intradermal application and rather low sensitivity.
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reproduction in any medium, provided the orpromising tool to overcome these problems [5-7]. Be-
cause IGRA use antigens specific to Mycobacterium tu-
berculosis, they do not show cross-reactivity with BCG
vaccination and most non-tuberculose mycobacteria. As
IGRA are in vitro tests, the problem of boosting in serial
testing is circumvented. IGRA correlate better than TST
with exposure to infectious patients and show a higher
sensitivity for active TB than TST [8]. Furthermore, in
low-incidence countries, IGRA have a higher predictive
value for disease progression [9-11]. Therefore, they are
likely to improve both the effectiveness and the effi-
ciency of HCW screening [12]. However, interpretation
of IGRA in the serial testing of HCWs remains to be
clarified and a consensus needs to be found [7,13-17].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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100,000 in 2007), however the variability of the inci-
dence rate is high. In the Paris region, the incidence rate
is as high as 18.4/100,000. Therefore TB prevention is
one of the highest public health priorities in France [18],
and special focus is given to nosocomial infections and
the screening of HCWs [19]. Since 2007, the French
Health Authority has recommended the use of IGRA for
these screenings. However, so far little is known about
the results of these IGRA TB screenings for French
HCWs. In the three small studies published so far, the
rate of IGRA positivity was 12% to 32% [19-21], while a
TST ≥ 10 mm was observed in 43% to 70% of HCWs.
However, all three studies comprised less than 300
HCWs in total.
As recommended, IGRA were introduced at the Uni-
versity Medical Centre of Nantes, France, to screen
HCWs for TB in 2007. In a retrospective study, TST and
IGRA results were compared and the effects of the
introduction of IGRA for TB screening on the number
of X-rays, referrals to the pneumology department for
further evaluation of TB and prescription of preventive
treatments were analysed. The annual attack rate for la-
tent TB infection (LTBI) was calculated based on differ-
ent definitions of IGRA conversion.
Method
The population of this cross-sectional study includes all
workers at the University Hospital of Nantes, France,
who participated in TB screening between May 2007
and May 2011 due to contact with infectious TB patients
or materials or because of pre-employment screening
and on whom an IGRA was performed. The University
Hospital of Nantes is the largest hospital in the Nantes
region and serves as a referral centre for TB patients
throughout the region.
Results were assessed retrospectively from the sub-
jects’ records. BCG vaccination for all newborns was
mandatory in France and until 2008 was repeated if the
TST was < 5 mm [22]. Therefore every HCW has been
vaccinated at least once. All identified HCWs were
French-born. As it was assumed that all HCWs were
vaccinated, no data on BCG vaccination was considered
in this analysis.
The TST was performed by trained personnel follow-
ing standard procedures. In brief, 0.1 mL (2 TU) of puri-
fied protein derivate (Tubertest from SanofiPasteur) was
injected intradermally at the volar side of the forearm
and the transverse diameter of the induration was read
after 72 to 96 hours. A diameter of ≥ 10 mm was consid-
ered positive. Following French guidelines [23], recent
LTBI is considered to be very likely if the TST is ≥
15 mm or the TST increase is ≥ 10 mm. Therefore these
definitions for a positive TST were considered, too.For the IGRA, the QuantiFERON® -TB Gold In-Tube
assay (Cellestis Limited, Carnegie, Australia) (QFT) was
administered in accordance with the manufacturer’s in-
structions. Data was extracted using a standardised data
sheet. The IGRA was performed either as a confirmatory
test for a positive TST or if a TST was contraindicated
or refused. Retrospectively, it was not possible to assess
why in particular an IGRA was performed and a TST
was not performed. The ethics committee at the Univer-
sity Medical Centre of Nantes gave its consent to this
anonymous retrospective data analysis.
Statistical analysis
Chi-square tests were used for categorical data. Adjusted
odds ratios (OR) and 95% confidence intervals (CI) were
calculated for putative predictive variables using condi-
tional logistic regression. Model building was performed
backwards using the chance criteria for variable selec-
tion. For calculation of the annual attack rate, it was as-
sumed that infections occurred continuously during the
follow-up. Therefore the mean of the follow-up period
was calculated in years and the annual attack rate is the
cumulative conversion rate divided by this mean.
Result
QFT results from 637 HCWs were assessed retrospect-
ively. Three (0.5%) results were indeterminate, while
positive QFT results accounted for 22.2% (Figure 1). The
description of the study population with determinate
QFT results is given in Table 1. Most HCWs were fe-
male (78.7%). Nurses constituted the largest single group
(34.2). 12.8% of the HCWs worked in the pneumology
department, 2.2% worked in the infectiology department
and 21.3% in the emergency room.
The TST was carried out on 466 HCW (73.5%). The
TST result was ≥ 10 mm in 77.4% of the HCWs (Fig-
ure 1). In those with a TST < 10 mm, QFT was positive
in 14.0% and in those with a TST ≥ 10 mm, QFT was
positive in 26.7%. The probability of a positive QFT in-
creased in line with the diameter of the TST. In those
with a TST between 10 and < 15 mm, it was 18.7% and
in those with a TST ≥ 15 mm it was 28.9% (Table 1).
This relationship remained statistically significant after
adjusting for age, gender, status, profession and depart-
ment (Table 2). An increase in TST diameter between 6
and < 10 mm or ≥ 10 mm was not associated with an in-
creased probability of a positive QFT (Table 1). No lin-
ear association between age and probability of positive
QFT was observed.
The QFT was repeated in 118 HCWs. The median
time between the two QFTs was 10.8 months (range: 0
to 47.5 months). Two QFTs were indeterminate (1.7%).
80.2% were negative in both QFTs and 10.3% were posi-
tive in both QFTs (Figure 1). The probability of
QFT performed n=637
undetermined n=3









































Figure 1 Flow chart of study population.
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to negative) was dependent on the interferon-(INF)-
gamma concentration in the first QFT (Table 3). Rever-
sion occurred in 40% of those with INF-gamma between
0.35 and < 0.7 IU/mL and in 14% of those with a higher
INF-gamma concentration in the first QFT. The total re-
version rate was 29% and the conversion rate was 6%.
Conversion occurred in 3.4% of those with a baseline
INF-gamma concentration < 0.2 IU/mL and in 27% of
those with a baseline concentration between 0.2 and <
0.35 IU/mL. If the definition of conversion is restricted
to those with a baseline concentration below 0.2 IU/mL,
and taking the time between the two tests into account,
the annual attack rate for LTBI is 4.1%. In a simple nega-
tive to positive approach, the annual attack rate is 7.3%
(no table).
56 HCWs (52 [92.9%] with positive QFT) had a con-
sultation with a pneumologist and 34 HCWs (32 [94.1%]
with positive QFT) were prescribed preventive treat-
ment. Four consultations and two preventive treatments
were based on a positive TST even though the QFT was
negative. No particular reason is known for this. Follow-
ing a positive TST (≥ 15 mm or an increase ≥ 10 mm),
289 (out of 466, 62.0%) HCWs would have received a
recommendation for a consultation with a pneumologist.
Out of these 289 HCWs, 283 had a TST ≥ 15 mm and
an additional six HCWs had a TST increase ≥ 10 mm
but with a TST result < 15 mm (no table). X-rays
performed by pneumologists did not reveal active TB.
The median follow-up of the HCWs after the first QFT
was 12 months (range: 0 to 48 months). No active TB
was observed. Introducing QFT into the TB screening
reduced recommendations for consultation with apneumologist from 62.0% in the TST-tested subgroup to
8.8% in the whole group.
Discussion
To our knowledge, this is the largest study comparing
the results of TST and IGRA screening for HCWs in
France. In HCWs considered to have a recent LTBI, fol-
lowing French recommendations for the interpretation
of TST results [23], only 28.6% were positive according
to the IGRA. No active TB was detected and no HCW
with a positive TST or IGRA progressed to active TB.
Therefore any decisions regarding further clinical evalu-
ation and preventive treatment should be based on
IGRA rather than TST alone.
A low confirmation rate of a positive TST was also
reported in the three smaller French studies [19-21] and
by other European HCW studies [24-26]. According to
these, the probability of a positive IGRA increased in
line with the diameter of the TST.
Prevalence of a positive IGRA was not associated with
working in departments with a likelihood of contact with
TB patients, e.g. pneumology, infectiology or emergency.
Again, this agrees with the above-mentioned European
studies which also failed to detect this association. In
contrast to these prevalence studies, Rafiza and Rampal
[27] observed an increased risk of LTBI for workers in
the emergency department (RR 2.2; 95% CI 1.07–4.4) in
their incidence study.
No linear trend between age and prevalence of positive
IGRA was observed in our data. This is in contrast to
data from Germany and Portugal [26,28], which de-
scribes a positive association between age and prevalence
of positive IGRA. As our study population comprises
Table 1 QFT results by demographic and occupational
factors
QFT negative QFT positive All
N % n % N % p-value
Female 386 77.4 113 22.6 499 78.7
Male 107 79.3 28 20.7 135 21.3 0.637
Age (years)
< 30 110 73.8 39 26.2 149 23.5
30 – < 40 153 79.7 39 20.3 192 30.3
40 – < 50 129 85.4 22 14.6 151 23.8
50+ 101 71.1 41 28.9 142 22.4 0.015
Status
Temporary 59 67.0 29 33.0 88 13.9
Student 45 86.5 7 13.5 52 8.2
Staff 389 78.7 105 21.3 494 77.9 0.015
Profession
Nurses 169 77.9 48 22.1 217 34.2
Physicians 52 88.1 7 11.9 59 9.3
Others 272 76.0 86 24.0 358 56.5 0.115
Department
Pneumology 67 82.7 14 17.3 81 12.8
Infectiology 10 71.4 4 28.6 14 2.2
Emergency 105 77.8 30 22.2 135 21.3
All others 311 77.0 93 23.0 404 63.7 0.656
TST
< 10 mm 92 86.0 15 14.0 107 16.9
10- < 15 mm 61 81.3 14 18.7 75 11.8
+15 mm 202 71.1 82 28.9 284 44.8
Unknown 138 82.1 30 17.9 168 26.5 0.003
TST increase
No increase 44 67.7 21 32.3 65 10.3
6- < 10 mm 17 65.4 9 34.6 26 4.1
+10 mm 34 79.1 9 20.9 43 6.8
Not tested 398 79.6 102 20.4 500 78.9 0.068
Total 493 77.8 141 22.2 634 100.0
Table 2 Adjusted odds ratios for a positive QFT
depending on age und TST*
Age (years) OR 95%CI
< 30 1 –
30 – < 40 0.7 0.4–1.3
40 – < 50 0.5 0.3–0.9
50+ 1.3 0.8–2.2
TST
< 10 mm 1 –
10- < 15 mm 1.4 0.6–3.1
+15 mm 2.5 1.3–4.5
*Status, TST increase did not meet the inclusion criteria.
Table 3 Results of second QFT depending on
concentration of first QFT
Second QFT
Negative Positive All
First QFT N % n % N %*
< 0.2 IU/mL 85 97 3 3 88 76
0.2–0.35 IU/mL 8 73 3 27 11 10
Negative QFT 93 94 6 6 99 86
0.35- < 0.7 IU/mL 4 40 6 60 10 8
+0.7 IU/mL 1 14 6 86 7 6
Positive QFT 5 29 12 71 17 14
*Column per cent.
Moucaut et al. Journal of Occupational Medicine and Toxicology 2013, 8:12 Page 4 of 6
http://www.occup-med.com/content/8/1/12HCWs on whom a QFT was performed, selection bias
might be responsible for the failed detection of the
expected association between age and LTBI prevalence.
For the same reason, our data does not allow for an un-
biased estimation of the LTBI prevalence in French
HCWs. HCWs with a negative TST are not likely to be
tested using QFT and therefore they are underrepre-
sented in our study. However, as was shown in our data,
probability of a positive IGRA is lower in those with a
TST < 10 mm compared to those with a TST ≥ 10 mm.
Although only limited observations were available,
conversion and reversion rates in our study were highand depended on concentrations in the first QFT. Again,
this was reported by other authors, too [13,29-33]. Clin-
ical decision-making should therefore consider the re-
cent exposure situation and the concentration of the
QFT. The reversion rate of QFT results between 0.35
und 0.7 IU/mL, albeit based on only a few observations,
was high (40%). This corroborates the recommendation
to use a borderline zone for the QFT of 0.2–0.7 IU/mL
for interpretation of QFT in the serial testing of HCW
[34]. Following this recommendation, a known, recent
contact with an infectious TB patient and a concentra-
tion in the QFT (> 0.7 IU/mL instead of ≥ 0.35 IU/mL)
make a recent infection likely.
Again based on just a few observations (6 out of 88),
the annual attack rate for LTBI was 7.3% with a simple
negative to positive interpretation of the IGRA, and
4.1% with a more prudent definition of a conversion
(trespassing from < 0.2 IU/mL to > 0.7 IU/mL). This at-
tack rate is about as high as the one reported for HCWs
in Malaysia [27] and far higher than the attack rate ob-
served in unexposed nursing students in Germany of <
1% [35], and it should be studied further. It indicates
that protection of HCWs should be improved. As masks
have proved to be an effective prevention measure, in-
fectious patients, and HCWs in close contact with these
patients, should be encouraged to wear masks [2].
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Introduction of IGRA in HCW screening will reduce the
number of X-rays and the referrals to the pneumology
department for further clinical evaluation. The annual
attack rate for LTBI in our preliminary data gives rise to
concerns. Preventive measures should therefore be im-
proved, flows in early detection of infectious patients
should be analysed, awareness of HCWs should be im-
proved through training and masks should be worn
more often, especially in emergency rooms as here pa-
tients are still undiagnosed.
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